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Philip Murray 
ABSTRACT 
Inhibiting protein-protein interactions to achieve a therapeutically 
desired effect has been a goal in the field of drug discovery for 
decades.  Recently, advances in peptidomimetics have led researches 
to the use of cyclized peptides to achieve this goal.  Cyclization of 
linear peptides restricts the number of conformations of the peptide, 
increasing the peptide’s affinity to binding to the desired target.  
Cyclization also stabilizes the peptide, allowing the peptide to be 
resistant to proteases.  This study explores the optimization of solution 
phase synthesis of an important integrin-mediated cell adhesion cyclic 
peptide for the therapeutic inhibition of multiple myeloma, cHYD1.  
cHYD1 was originally synthesized via solid phase peptide synthesis, 
and the need for a scaled up synthesis version was needed after 
positive bioactivity results were obtained.  Chapter 3 includes the 
molecular modeling exploration of a possible new mechanism to which 
cyclized peptides could work, in which, rather than a recognition and 
non-recognition strand being implemented, a specific directional face is 
used for protein-protein interaction.  This was done with the 
xii 
 
implementation of an antagonistic cyclic peptide to replace human 
growth hormone in its interaction with the human growth hormone 
receptor, and the subsequent di-cyclic peptide agonist.   
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CHAPTER ONE: 
INTRODUCTION 
 
1.1 Peptide and protein overview 
 Proteins are biological macromolecules composed of one or more 
polypeptides folded in a globular fashion that facilitates a biological 
function.  These polypeptides are made up of linear chains of amino 
acids.  A peptide is a linear chain of two or more amino acids, linked 
via amide bonds.  A chain of 2 to 100 amino acids and carrying a 
molecular weight of less than 10 kDa is usually defined as a peptide, 
while longer chains reflect polypeptides, those with defined structure 
and function being referred to as proteins.   
There are 20 naturally occurring amino acids, with countless 
other synthetic mimics and analogs.  Each amino acid contains an α-
carbon, to which a carboxyl group, an amino group, and a variable 
side chain which defines the given amino acid are attached.  The 
combination of the variable side chains in a peptide and/or protein 
structure inevitably give rise to the conformation and biological activity 
of the specific analog.  Amino acids link together via an amide bond, 
2 
 
specifically being referred to as a peptide bond.  In laboratory 
synthesis, the carboxylate end of a given amino acid must be 
“activated” via a coupling agent.  The amine group of the second 
amino acid then creates a nucleophilic attack on the carbonyl of the 
first amino acid, producing a peptide bond while releasing a molecule 
of water.  The free carboxyl end of the peptide is known as the C-
terminus, while the free amino end of the peptide is known as the N-
terminus (Fig 1.1).  Amino acids within a peptide are referred to as a 
“residue”.   
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Fig 1.1 Peptide Bond Formation 
 
The peptide bond has some double bond characteristics due to 
resonance, inhibiting free rotation around the bond (1), leaving the 
backbone α-carbons in a coplanar state.  The other dihedral angles 
determine the shape of the particular peptide.   
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Fig 1.2 Resonance structure of a peptide bond 
 
The primary structure of a protein is that of a linear peptide.  
When folded among other peptides, secondary structures such as α-
helices, β-sheets, and β-turns are produced.  These secondary 
structures come about via geometrical bond angles between amino 
acid residues and hydrogen bonds between adjacent amino acid 
residues, stabilizing the structure.  When these secondary structures 
interact and fold among themselves, the tertiary structure of the 
protein is born, giving rise to its three-dimensional shape, leading to 
the protein’s basic biological function.  This is held together by 
hydrogen bonds, disulfide bonds, and sometimes salt bridges.  The 
quaternary structure of a protein is the intermolecular interaction of 
two or more tertiary structures, leading to a protein complex which 
works in unison for a given biological activity.   
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1.2 Secondary Structures 
 The predominant secondary structures of proteins are α-helices, 
β-sheets, and β-turns.  The right-handed α-helix structure makes up 
roughly 31% of all protein structures, while β-sheets make up 28% 
and β-turns make up 25%, respectively (2).  These structures allow 
opportunities for drug design to mimic such folding, providing a 
synthetic recognition surface capable of simulating protein-protein 
interactions, further accentuating or inhibiting downfield chemical 
responses associated with the given protein’s biological activity. 
 The α-helix (Fig 1.3) is a coil usually formed in a right-handed 
conformation.  Each main-chain nitrogen of a peptide donates a 
hydrogen to the oxygen of the main-chain carbonyl exactly four 
residues downfield, forming a hydrogen bond.  Each residue allows for 
a 100° turn.  There are 3.6 residues per turn at a translation of 1.5 Å 
along the axis, giving an overall vertical distance of 5.4 Å per turn.  
Methionine, alanine, leucine, uncharged glutamine, and lysine have the 
highest propensity to helical formation, while glycine and proline have 
the lowest.  Glycine seems to be too flexible in allowing a helical 
conformation to occur, while proline is too rigid and does not the 
propensity to form a main-chain hydrogen bond (3).  Alpha-helices are 
involved in DNA binding, cell-membrane crossing, and some 
mechanical properties. 
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Fig 1.3 Alpha Helix 
 
 β-sheets are important secondary structures for protein-protein 
and protein-DNA interactions, creating desired and undesired biological 
functions.  β-sheets comprise of two or more β-strands, running either 
parallel (Fig 1.4) or anti-parallel (Fig 1.5) to each other.  The direction 
is determined from N- to C-terminus.  Hydrogen bonding between the 
α-nitrogen of one strand and the nearer carbonyl of the other adjacent 
strand produces the stability and conformation of the sheet.  Anti-
parallel β-sheets have shorter, more stable hydrogen bonds than their 
parallel counterparts.  Both parallel and anti-parallel β-sheets have 
adjacent side-chain residues which point in opposite directions, leaving 
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an extended conformation.  This allows for recognition at both the top 
and bottom faces of the sheet.  Parallel β-sheets are usually found in 
the hydrophobic core of proteins, whereas anti-parallel β-sheets 
usually display amphipathic characteristics and can be found at the 
surface of proteins.  Amino acids with high β-sheet propensity include 
tyrosine, phenylalanine, tryptophan, threonine, valine, and isoleucine.   
 
Fig 1.4 Parallel Beta Sheet.  Hydrogen bonds are depicted by dotted lines.  Arrows 
point from N- to C-terminus. 
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Fig 1.5 Anti-parallel Beta Sheet.  Hydrogen bonds are depicted by dotted lines.  
Arrows point from N- to C-terminus. 
 
 
 The β-turn (Fig 1.6) is an extremely important biological 
structure, as it allows for a peptide to complete a 180° turn, allowing 
for ease in folding, creating a globular shape, and providing synthetic 
access for protein-protein recognition (4-6).  They consist of loops of 
four residues, involving a hydrogen bond between the ith and ith+3 
residues, stabilizing the turn.   
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Fig 1.6 Beta Turn 
 
 The β-turn has led to the discovery of the β-hairpin (Fig 1.7), 
and in turn β-hairpin mimics, which have a wide variety of functional 
use in drug discovery.  The β-hairpin is the simplest form of two β-
sheets formed together in an anti-parallel arrangement linked by a 
short loop of two to five residues which form a loop or turn.  They vary 
widely in their formation, occurring in isolation or as a series of 
hydrogen bonds (7). 
10 
 
 
Fig 1.7 Beta Hairpin 
 
1.3 Peptidomimetics 
 Peptidomimetics is the strategy of synthetically imitating a 
peptide via some sort of molecular modification in an attempt to 
advantageously alter the molecular properties of the peptide.  This is 
done in a non-natural environment, such as integrating non-natural 
amino acids or the alteration of the normal peptide backbone.  This 
process has a significant role in drug discovery. 
 D-peptides, derived from the sequencing of D-amino acids, have 
long been a tool of peptidomimetics.  D-amino acids rarely occur 
naturally in comparison to their L-amino acid counterparts.  Their side-
chains are the mirror image of the L-amino acid versions.  They are 
not easily digested or degraded, and can have a low immunogenic 
response, allowing for an attractive drug model (8).   
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 More importantly, peptidomimetics has recently headed towards 
the mimicking of β-hairpins as a way to increase protein-protein 
interaction and increase biological activity with drug-based peptides.  
The approach is to replace a hairpin loop of a known structure with a 
template that stabilizes the β-hairpin.  This template is known as the 
β-turn promoter, and facilitates a cyclic β-sheet conformation.  These 
turn promoters have been varied greatly, using both natural and non-
natural amino acids.  Originally, Blanco, et al, found that the L-Asn-Gly 
dipeptide was an efficient β-turn promoter (Fig 1.8) (9). This was later 
surpassed by Gellman’s group, using D-Pro-Gly as the template, 
signifying the use of D-amino acids as an increased model for β-hairpin 
conformation (Fig 1.9) (10).  Since these discoveries, a myriad of 
different groups have reported a vast array of β-turn promoters, 
ranging from simple dipeptides to complex non-natural amino acid 
derivatives (11-13). 
 
Fig 1.8 L-Asn-Gly turn promoter 
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Fig 1.9 Gellman peptide, D-Pro-Gly turn promoter 
 
 1.3.1 Cyclic Peptidomimetics 
 Linear peptides are poor synthetic drugs, as they are too 
conformationally flexible, existing as random structures in solution.  
This leads to low bioavailability, and they are easily degraded by 
proteases in the body.  This can be combatted by restricting the 
flexibility of the molecule via cyclization, making the structure 
extremely rigid.  Molecules designed in a prearranged conformation 
and owning a fixed shape are better recognized by their targets due to 
the lower amount of entropy loss associated with binding, leading to a 
higher affinity for the target and, theoretically, higher desired 
biological activity.  Cyclic peptides also cannot be recognized by 
proteases, allowing for a longer lifespan for the drug.   
13 
 
In using β-hairpin mimicking schemes, a peptide can be 
completely cyclized using a β-turn promoter on both ends of the 
cyclized product.  The core residues are placed on the recognition 
strand, while the non-recognition strand can be used to optimize 
bioavailability and bioactivity.   
 Kopple, et al, originally used a D-Pro-L-Pro template to 
accomplish cyclization, proving β-sheet structures can be attained with 
such a β-turn promoter (14).  Robinson, et al, used this template 
extensively, including forming a cyclic peptide that inhibits p53/MDM2 
interaction (Fig 1.10) (15).  This template is discussed further in 
Chapter 3 as a way to develop and model a particular cycle peptide.  
McLaughlin, et al, developed a non-natural amino acid derivative, 
methylsulfonamido aminoethyl glycine (Fig 1.11) (unpublished 
results), as another stable β-turn promoter which is used later in 
Chapters 2 and 3, as well.   
14 
 
 
Fig 1.10 Robinson Cyclic Peptide, D-Pro-L-Pro turn promoter 
 
Fig 1.11 McLaughlin β-turn promoter 
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1.4 Solid Phase and Solution Phase Peptide Synthesis 
 Solid Phase Peptide Synthesis (SPPS) was originally designed by 
Robert Merrifield in 1959, authoring a paper in 1963 describing his 
work (16).  The principle behind SPPS is the binding of the peptide to 
an immobilized solid support system, usually a polymeric resin bead.  
After reaction of each adjacent amino acid in a step-wise fashion, 
unreacted reagents are easily washed away with solvent before 
proceeding to the next step.  Eventually, the peptide is cleaved from 
the resin, leaving just the desired product.  Scheme 1.1 represents 
SPPS, including amino acid deprotection and activation.   
16 
 
 
Scheme 1.1 Solid Phase Peptide Synthesis Scheme 
 
 SPPS is advantageous in that it uses an immobilization scheme 
throughout the synthesis.  This allows for easy isolation of the 
17 
 
compound and its intermediates through synthesis.  Bead 
manipulation can be performed depending on the sequence desired.  
SPPS is easily automated, and reactions are relatively clean, as little to 
no purification is needed.  However, disadvantages of SPPS include 
poor reaction monitoring, the necessary need for sometimes complex 
correct linkers between the resin and the desired product, and the fact 
that excess reagents are used, causing an extremely wasteful and 
costly environment. 
 In comparison, solution phase peptide synthesis includes an easy 
understanding of reaction development, as peptide synthesis has been 
known for decades.  There is no need for excess reagents, as all 
reagents can be used on an equivalent scale.  Reaction monitoring is 
also relatively easy.  Most importantly, solution phase synthesis can be 
scaled up to large quantities while incurring very little in cost.  
Automation does take some creativity, and purification steps are 
needed, but both can be limited with enough resources.  Chapter 2 
explains in full detail the scaling up of a peptide originally synthesized 
via SPPS.   
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1.5 Protecting Groups  
 With peptide synthesis, the use of protecting groups is essential 
to the desire to create clean product with no unnecessary side 
products.  The primary amine of the main-chain of an amino acid, as 
well as primary amines on any given side-chains, is very reactive with 
any free carboxyl group available, especially after carbonyl activation.  
If protecting schemes were not employed, a myriad of different 
reactions would occur involving both unprotected ends of the amino 
acid (Fig 1.12).   
 
Fig 1.12 Unprotected Amino Acid Synthesis 
 
 Protecting groups are employed to curb such reactions, inhibiting 
the nucleophilic attack needed to form a peptide bond due to steric 
hindrance.  These are bulky groups placed on the free amino and free 
19 
 
carboxyl groups that can be removed via different mechanisms, such 
as the addition of acid, base, or by hydrogenolysis.  They are defined 
by their deprotection or removal schemes, such as being “acid labile” 
for acid removal and “base labile” for base removal.  Some protecting 
groups are removed via hydrogenolysis, the process of hydrogen being 
used to cleave carbon-carbon or carbon-heteroatom bonds (17).  For 
our work later, it will be shown that we use a palladium catalyst on 
carbon along with a hydrogen source to elicit the deprotection. 
 For solution phase synthesis, carboxyl protecting groups 
primarily include methyl esters (strong acid or base labile), tert-butyl 
esters (acid labile), benzyl esters (removed by hydrogenolysis), and 
allyl esters (removed via palladium catalyst).  Other lesser used 
carboxyl protecting groups include silyl esters (acid or base labile) and 
oxazolines (strong acid labile). 
20 
 
 
Fig 1.13 Common Carboxyl Protecting Groups 
 
 Amino protecting groups consist primarily of 9-
fluorenylmethyloxylcarbonyl (Fmoc, base labile), tert-butyloxycarbonyl 
(Boc, acid labile), and carboxybenzyl (Cbz, removed by 
hydrogenolysis).  Other protecting groups include tosyl, benzyl, and 
acyl groups.   
21 
 
 
Fig 1.14 Common Amino Protecting Groups 
 
1.5.1 Orthogonal Protection Schemes 
 The orthogonal protection scheme was first introduced by Robert 
Merrifield in 1977 (18).  This scheme allowed for different protecting 
groups to be deprotected selectively, leaving only one local area open 
for attack within a given peptide bond formation.  If a C-terminal 
carboxyl group is protected via a base labile protecting group, then the 
amino acid or corresponding peptide’s N-terminal amine would be 
protected with either an acid labile group or a group readily removed 
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by hydrogenolysis.  If a side-chain or side-chains necessitating a 
protecting group were present, then all side-chains would be protected 
with similar labile protecting groups, and not carrying the same 
labiality as either the N- or C-terminus.  Later, we explore a situation 
in which ultimately the orthogonal protection scheme needed for our 
cHYD1 peptide gives rise to a C-terminal methyl ester protecting group 
(base labile), an N-terminal Cbz protecting group (removed via 
hydrogenolysis), and side-chain amines consisting of Boc protecting 
groups (acid labile).  Since Merrifield, numerous studies have 
developed similar and more complex orthogonal protection schemes 
(19). 
 
1.6 Coupling Agents 
 Without any help, formation of the peptide bond between the 
amino group of one amino acid and the carboxylic group of another 
amino acid is energetically unfavorable.  In nature, this is overcome by 
enzymes that catalyze the reaction.  The enzymes “activate” the 
carboxyl group, making the carbonyl carbon a better electrophile, 
allowing for the free amine of the other amino acid to perform a 
nucleophilic attack.  This can be mimicked in synthesis via coupling 
agents.  The hydroxyl group is replaced by an electron withdrawing 
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substituent, enhancing the electrophilicity of the carbonyl.  Fig 1.15 
shows the mechanism of activation with N,N’-dicyclohexylcarbodiimide 
(DCC).  After activation, the group is a very strong electron 
withdrawing group, allowing for nucleophilic attack by the free amine 
of the incoming amino acid (Fig 1.16).  
 
Fig 1.15 DCC activation 
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Fig 1.16 Peptide Bond Formation After Activation 
 
 There are generally two types of activating agents used in 
peptide synthesis: carbodiimides and triazoles.  Carbodiimides were 
first developed for this use, the most notable version being DCC 
referenced above and the original activating agent used in the solution 
phase synthesis of cHYD1 mentioned in Chapter 2.  Carbodiimides, 
while useful, yield insoluble urea which must be eliminated through 
purification.  They are also too reactive, sometimes causing 
racemization of the amino acid.  To combat this, triazoles such as 1-
hydroxybenzotriazole (HOBT) were developed.  They are less reactive, 
giving less danger to racemization.  Since the development of 
triazoles, newer activating agents have evolved, eliminating the use of 
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carbodiimides completely.  They include the use of uronium and 
phosphonium salts to help with activation.  One such activating agent, 
HCTU, is now used regularly for SPPS in our lab with a high degree of 
success.  Fig 1.17 shows the common coupling agents used in current 
peptide synthesis procedures. 
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Fig 1.17 Common Coupling Agents (courtesy Dr. Priyesh Jain) 
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CHAPTER TWO: 
cHYD1 SOLUTION PHASE SYNTHESIS OPTIMIZATION 
 
2.1 Introduction 
 Multiple Myeloma (MM) is an incurable hematopoietic malignancy 
due to the lack of elimination of minimal residual disease (MRD) and 
the strong multi-drug resistance (MDR) emergence of tumor cells 
following standard chemotherapeutic treatments (1).  MRD is found in 
the bone marrow compartment, indicating that the bone marrow 
environment allows for chemical signaling that includes the failure to 
eliminate MRD, leading to re-emergence of the disease (2).  
Hazlehurst, et al, have shown that adhesion of hematopoietic cells 
such as MM tumor cells to fibronectin (FN) in the extracellular matrix 
stimulates tumor cell survival and prompts chemotherapeutic drug 
resistance, referred to as cell adhesion mediated drug resistance, 
CAM-DR (3-9).  The disruption of the tumor-stromal cell adhesion has 
since been the focus of a variety of research groups to increase the 
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efficiency of standard chemotherapeutic treatments as a way of 
eliminating MRD and avoiding MDR.   
 Using combinatorial peptide libraries and a functional binding 
assay, Cress, et al, identified several peptides that inhibited β1 
integrin mediated cell adhesion of prostate cancer cells to fibronectin, 
laminin, and collagen IV (10). Ultimately, the lead peptide derived 
from these studies was determined to be the all D-amino acid peptide 
referred to as HYD1 (kikmviswkg), which prevents integrin binding 
epithelial prostate carcinoma cells with extracellular matrices (11, 12).  
The inhibition of cell adhesion was attributed to dissociation of 
adhesion and resulting signaling events downstream rather than by 
cell death (9, 13, 14).  Hazlehurst, et al, have shown that HYD1 blocks 
α4β1 integrin mediated adhesion of MM cells to fibronectin, increasing 
the efficiency of standard chemotherapeutic treatments against MM 
(15).  The same study has shown that HYD1 works similar to RGD 
(Arg-Gly-Asp) motif peptides, which block integrin ligand interactions.  
However, unlike RGD peptides, which induce apoptic cell death 
independent of the presence of the ligand via activation of caspases, 
release of apoptosis-inducing factor, and induction of double stranded 
DNA breaks signifying endonuclease activation (16), HYD1 causes 
necrosis via the loss of the mitochondrial membrane potential, loss of 
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total cellular ATP, and an increase in reactive oxygen species (ROS) 
production.  This happens as a single event in vitro and in vivo (15).   
 Hazlehurst, et al, performed truncated N- and C-terminus 
studies on D-HYD1, leading to the discovery of the MVISW region as 
the likely core region for biological activity.  Further studies showed 
that replacing I with V further improved biological activity of the D-
HYD1 analog.  The strategy of cyclizing linear peptides as a means to 
limit the number of conformations available is a well-known strategy 
that increases the affinity of the binding of the peptide to the target, 
allowing for a beta-hairpin turn that further constrains the peptide into 
a beta-sheet conformation.  This also allows for the amide bonds to 
not be recognized by proteases, allowing for an extremely stable 
compound.  The cyclization of D-HYD1 (cD-HYD1) allowed the MVVSW 
recognition strand region to be in this beta-sheet-like conformation, 
and produced a 2-fold increase in activity over the linear D-HYD1.  The 
non-recognition strand was determined to be KLKLK, in theory to help 
with the amphipathicity of the overall compound.  The corresponding 
cyclic version of L-HYD1 actually increased biological activity another 
2-fold.  Structure-Activity Relationship (SAR) studies showed that 
replacing S with A and M with nor-Leucine further improved biological 
activity.  Various turn promoters, to help with cyclization and further 
stabilize the beta-sheet conformation, were explored, eventually 
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settling on a methylsulfonamido aminoethyl glycine derivative on one 
side and a d-Prolinol derivative on the other.  All of these studies 
eventually gave rise to cHYD1 (Fig 2.1 and 2.2), with an IC50 of 1.2 
µM, as compared to the lead D-HYD1 IC50 of 31.8 µM.   
 
Fig 2.1 cHYD1 Structure 
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Fig 2.2 cHYD1 via molecular modeling  
 
2.1.1 Solution Phase Synthesis Strategy 
 It was determined that the best route for overall synthesis of 
cHYD1 via solution phase was to synthesize it fragmentally.  The idea 
would be to synthesize the non-recognition strand with one turn 
promoter (referred to as “linker”) separate from the recognition strand 
with another turn promoter (“linker”).  The two subsequent hexamers 
would then be coupled together at one end first, creating the linear 
12-mer, which would then be cyclized, resulting in the final cHYD1 
product.  This route of synthesizing fragments was thought to be most 
beneficial, as it would minimize any loss that could occur with further 
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additional couplings, as well as minimize aggregation of the growing 
peptide, theoretically allowing for better overall yields with each step.  
The following scheme (Scheme 2.1) and report are strictly from the 
non-recognition strand synthesis development, as Hyun Joo Kil was 
respectively placed on recognition strand synthesis development.     
 
Scheme 2.1 Synthesis Scheme for cHYD1 Non-recognition strand 
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2.1.2 Coupling Agents 
 While DCC/HOBT is the preferred coupling agent system for most 
solution phase peptide synthesis schemes, a newer reagent, ®T3P has 
made its way to the market.  ®T3P has its advantages in that 
purification is easy, subsequent yield is high, epimerization and 
toxicity are low, and it is relatively inexpensive.   
Table 2.1 Coupling Agent Comparisons (17) 
 
 ®T3P actually has three active sites, activating the carboxyl 
group of the amino acid, and producing a water-soluble side-product 
which is easy to remove (Fig 2.3). 
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Fig 2.3 ®T3P Mechanism (17) 
 
2.2 Linker Development 
2.2.1 Tert-butyl-2-aminoethylcarbamate 
 The linker was derived initially from its obvious root, 
ethylenediamine.  In order to ensure proper alkylation to only one of 
the free amines, the other side must first be protected, preferably via 
a Boc group for a viable orthogonal scheme.  This was done through 
the introduction of di-tert-butyl dicarbonate.  Extremely dilute 
conditions were needed so as to only produce the mono-protected 
substituent.  It was found that the use of nine equivalents of 
ethylenediamine to di-tert-butyl dicarbonate with a relatively large 
amount of protic solvent (in this case, tetrahydrofuran, THF) at 0°C 
was sufficient.  These dilute conditions combined with the cold 
temperature allowed for the reaction rate to be slowed down enough 
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to allow for only mono-protected substituent to be produced.  Any 
smaller ratio resulted in some unwanted di-protected substituent, and 
any larger ratio would just result in more excess waste.  Purification of 
the final mono-protected product was unnecessary, as a simple water 
workup and concentration was sufficient in removing any excess 
ethylenediamine.   
 
2.2.2 Tert-butyl (2-(methylsulfonamido)ethyl)carbamate 
 Originally, the next step was to develop methyl 2-((2-((tert-
butoxycarbonyl)amino)ethyl)amino)acetate, involving the N-alkylation 
of tert-butyl-2-aminoethylcarbamate via the use of methyl 
bromoacetate.  While the reaction was simple and efficient, albeit 
somewhat lengthy in time, purification via chromatography was 
necessary.  This would prove costly financially, time-wise, and in yield.  
To avoid this problem, a different route was explored successfully.  
Rather than first N-alkylating then adding the methylsulfonyl group to 
attain the linker, the order was reversed.  Methanesulfonyl chloride 
was added in a 1:1 ratio to tert-butyl-2-aminoethylcarbamate in the 
presence of triethylamine (TEA) for one hour.  After water workup and 
concentration, the product was found to be an off-white solid at a 
90.8% yield and with only one TLC spot and a clean LCMS profile.  This 
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step essentially increased yield, shortened the overall reaction time 
(24 hours to 1 hour), and eliminated the need for a costly 
chromatography purification.   
 
Scheme 2.2 Linker Purification Scheme 
 
2.2.3 Methyl 2-(N-(2-(tert-
butoxycarbonylamino)ethyl)methylsulfonamido)acetate, Boc-
Linker(OMe) 
 The final step in the development of the linker was to N-alkylate 
the secondary amine with the methanesulfonyl group attached to it.  
First, the proton needed to be pulled off.  This was done via sodium 
hydride.  Once this was done, methyl bromoacetate was introduced in 
a 1:1 ratio to the starting material.  After water was used to quench 
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any remaining sodium hydride an hour into the reaction, a water 
workup and concentration revealed a crude solid product.  
Recrystallization of the pure product was realized through a 1:1 ethyl 
acetate:hexane mixture, revealing a white solid with a pure TLC and 
LCMS profile.  Thus concluded the development of the linker without 
the need for any costly purification steps and done in a quick and easy 
manner. 
 
2.2.4 Linker Deprotection 
 As with most deprotections of Boc groups in peptide chemistry, 
trifluoroacetic acid was first used to deprotect the linker to allow for 
the free amine to be ready for amino acid coupling.  Unfortunately, 
removing excess trifluoroacetic acid via a normal water workup was 
not possible.  The deprotected linker is hydrophilic given the nature of 
its free amine and methylsulfonyl group and goes into the water layer 
in any organic/water extraction process.  Attempting to remove excess 
trifluoroacetic acid via rotovap seemed ideal given its relatively low 
boiling point (72.4 °C), however, trace amounts were still left behind 
without regard to the amount of excess trifluoroacetic acid used.  Even 
using excess DIEA in an attempt to neutralize the solution did not 
completely remove it.  This ultimately contributed to the lower yields 
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in the dimer synthesis step, as the carboxylate of trifluoroacetic acid 
would be activated via the coupling agent, essentially capping a 
somewhat significant portion of linker. 
 Very recently, our group has discovered the use of 
methanesulfonic acid as a viable alternative to trifluoroacetic acid as a 
means to deprotect the Boc group from the linker.  Methanesulfonic 
acid deprotection yields an inert side product that does not interfere 
with coupling, and can be easily neutralized via DIEA.  Four 
equivalents of methanesulfonic acid are needed, which results in a 
deprotection time of less than ten minutes.  DIEA would then be used 
at a slight excess to neutralize the remaining solution so as not to 
allow for further side-chain Boc group deprotection of the following 
amino acid coupling (in this instance, Z-Lysine(Boc)-OH), followed 
immediately by the next coupling step.  This procedure decreases 
overall time needed for synthesis, as the painstaking task of 
attempting to remove excess trifluoroacetic acid is eliminated, saving 
up to a couple days in time overall.  Preliminary data also shows that 
the subsequent overall dimer yield is increased. 
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2.3 Amino Acid coupling 
 The original idea for the amino acid coupling steps would be to 
simply use DCC/HOBT as the coupling agents, a well-regarded process 
in solution-phase peptide synthesis.  While this process works for our 
synthesis, purification is problematic, as there is a need to remove the 
unwanted urea derivative, and usually involves costly column 
chromatography.  Other coupling agents were explored in an attempt 
to avoid such purification, eventually leading to the use of ®T3P.  ®T3P 
provides a clean and efficient coupling, and can be easily removed 
through a water extraction.   
 The other consideration for synthesis was the orthogonal 
protection scheme needed for the subsequent amino acids.  Given that 
the linker was protected on the C-terminal end with a methyl ester, a 
base labile protecting group, the main-chain amines as well as the 
side-chain amine of each lysine group could not be of the same nature.  
Therefore, Fmoc was immediately eliminated from consideration.  The 
first idea was to mimic the linker protection scheme, using the Boc 
group to protect the main-chain amines.  This would mean the side-
chain amine of each lysine would need to be protected by a group that 
was not either base or acid labile, leading to the use of the 
carboxybenzyl (Cbz) protecting group.  Unfortunately, this led to a 
dimer product that was oily in nature, causing purification problems, 
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including the use of column chromatography, and resulting in low 
yields.  However, when the protecting groups were switched, allowing 
for a Cbz protected main-chain amine along with a Boc protected side-
chain amine of lysine, the product was found to be solid in nature, 
allowing for easy, non-column aided purification, resulting in a drastic 
cut in overall synthesis costs financially and time-wise.  It also meant 
that trifluoroacetic acid would not be needed for any subsequent 
deprotections during the entire synthesis scheme, as simple 
hydrogenation was the method used to remove the Cbz group from 
each main-chain amine prior to coupling. 
 
2.3.1 Dimer Synthesis 
 After linker deprotection, the first amino acid in the sequence, 
lysine, was introduced.  This was done via commercially available Z-
Lysine(Boc)-OH.  After trifluoroacetic acid deprotection of the linker, 
the free amine compound was dissolved in DCM and treated with 2.5 
equivalents of DIEA.  While on a small scale this was not too difficult, 
at a larger, 2 gram scale, the compound proved difficult to dissolve.  
The trifluoracetic acid salt seemed to be the culprit, as 40mL of DCM 
was needed for complete solvation, which still was not fully realized 
until the introduction of the DIEA.  Once the compound was in 
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solution, 1.0 equivalent of Z-Lysine(Boc)-OH was added, the solution 
was cooled to 0°C, and T3P® was added.  The company that 
produces ®T3P, Archimica, recommends using 1.2 equivalents of ®T3P 
per coupling.  Our results show that increasing this to 2.0 equivalents 
seemed to be most ideal, especially as the scale of the reaction was 
increased.  Anything beyond 2.0 equivalents of ®T3P seemed to cause 
purification issues, possibly due to the cagey, oily nature of the 
reagent.  The reaction was under dry conditions at all times, as water 
cannot be present due to possible peptide bond hydrolysis as well 
as ®T3P quenching.  While the reaction seemed to near completion via 
TLC (100% ethyl acetate) in an hour, it was allowed to run overnight 
to maximize coupling time.  After the reaction was observed to be 
done via TLC, water was used to quench any remaining ®T3P.   The 
resulting solution was concentrated, and then dissolved in ethyl 
acetate.  At larger scales, some crude product precipitated under 
100% ethyl acetate conditions.  This precipitate was filtered off, and 
the filtrate was extracted three times with water.  This removed the 
majority of the excess ®T3P, its side product derivatives, and any 
unreacted free amine linker.  The organic layer was concentrated, and 
the crude solid product was added to the previous precipitate. 
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2.3.1.1 Dimer Purification 
 Given that the crude product was solid in nature, 
recrystallization was the preferred method of purification.  Several 
different ratios of ethyl acetate:hexanes were attempted without much 
success.  Finally, the use of 100% di-ethyl ether afforded the desired 
pure product, precipitated as a white solid in roughly an hour.  The 
ether layer consisted of any remaining ®T3P and side products, as well 
as any unreacted Z-Lysine(Boc)-OH, making it the perfect purification 
solvent.  This made for a cheap, easy, and quick purification scheme. 
 
2.3.1.2 Dimer Yield 
 The yield for the dimer at the larger scale was maximized at 
54.6% through the above conditions.  As mentioned earlier, 
trifluoroacetic acid played a role in limiting the synthesis of the dimer, 
through its carboxylate activation via ®T3P.  Preliminary data shows 
this problem to be alleviated using methanesulfonic acid as the 
deprotection mechanism.   
Another cause for low yield is the free amine linker itself.  Given 
that it is a six atom compound, it seems that a certain percentage is 
self-cyclizing, creating a six-member ring that is extremely stable.  
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This compound is found in the ether layer during the purification step, 
therefore there’s no carry over to the following coupling steps.   
 
2.3.2 Cbz Deprotection 
Before the coupling of the trimer and subsequent amino acids, 
the Cbz group of the main-chain amine must be removed.  This is 
done via hydrogenation along with a palladium catalyst.  The 
procedure used involved methanol as the solvent, with 10% palladium 
on carbon powder as the catalyst.  Hydrogen is then pumped into the 
reaction vessel at 55psi, and the mixture is allowed to stir overnight, 
giving way to the free amine.  At the 2 gram scale, 100mL of methanol 
is needed to dissolve the protected compound.  The reaction is filtered 
through celite, the filtrate is concentrated, and the resulting free 
amine is found at quantitative yields.   
There have been some attempts to find alternative hydrogen 
sources rather than pressurized hydrogen, as the idea to scale up to 
much larger industrial levels will leave the current procedure to 
become unrealistic.  Ammonium formate was first used, as the 
compound decomposes into ammonia, carbon dioxide, and hydrogen 
gas when placed in methanol. This would conceivably be an easy 
reagent to remove in excess, however, that was not found to be the 
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case, as ammonium formate would be found post-reaction in every 
instance regardless of time spent in reaction and under vacuum.   
Formic acid was also used, as it decomposes into carbon dioxide 
and hydrogen gas when placed in methanol, and is a liquid at room 
temperature, allowing for easier measuring and transferring methods.  
While the reaction happened almost instantaneously, resulting in full 
Cbz deprotection in a matter of seconds, the main problem seemed to 
be the removal of all excess formate salt.  The formate acted in the 
same manner as the trifluoroacetate in the Boc deprotection, being 
activated via ®T3P in the next coupling step, and interfering with 
coupling and subsequent yield.  This side product was also practically 
impossible to separate from the pure products.  In both the 
ammonium formate and formic acid deprotection schemes, a water 
workup could not be performed because the free amine compound is 
too hydrophilic and goes into the water layer.   
Very recently, triethylsilane was used as a hydrogen source.  A 
minimal amount of methanol was used to dissolve the dimer, 400mg 
of Pd(10%)/C was added, and 4 equivalents of triethylsilane was 
added.  The reaction went to completion in under one minute.  The 
side product is inert, and is easily removed via rotovap, along with the 
excess triethylsilane.  Triethylsilane could be a very promising Cbz 
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deprotection scheme moving forward, as it minimizes solvent and 
reaction times, allowing for a more cost- and time-effective reaction. 
 
2.3.3 Subsequent Amino Acid Couplings 
 Once the reaction conditions were maximized for the dimer, the 
remaining amino acids were coupled mimicking these conditions.  In 
the trimer synthesis, the original deprotected dimer was dissolved in a 
minimal amount of DCM (at the 2 gram scale, 13mL was used), as 
there was no trifluoroacetate salt present to cause solvation problems.  
This allowed for a much more concentrated solution, which 
theoretically allowed for better and quicker coupling due to the closer 
nature of the molecules present.  Further down the synthesis scheme, 
as the compound became larger, a little more DCM was needed 
(15mL) for solvation, as the compound was actually absorbing the 
DCM at smaller volumes.  Once the smallest volumes of DCM were 
realized for solvation, the yields increased dramatically, giving way to 
anywhere between 74.5% (pentamer) to a high of 89.5% (hexamer) 
yield.   
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2.4 Future Considerations 
 Some future considerations for the complete synthesis of cHYD1 
can be centered on the desire to lessen overall costs involved in the 
synthesis.  This includes the elimination of all columns, which are still 
present in the recognition strand synthesis.  The most ideal way to do 
this would be to synthesis the entire peptide linearly and then cyclize, 
rather than the current method of synthesizing the non-recognition 
strand and recognition strand separately before coupling the two 
strands together.  The theory behind this linear synthesis suggestion 
comes from the fact that the entire non-recognition strand produces a 
solid at each step and a subsequent easy purification process via 
simple recrystallization.  If this is the case, it is theorized that the non-
recognition hexamer can help each new coupling have the same 
overall nature, as we know the entire linear cHYD1 falls into this 
category as well. Currently, the recognition strand synthesis involves 
purification via a column after each coupling. 
 The other idea in lessening costs would be to lessen the amount 
of reagents and solvents needed per step.  In some instances, ®T3P 
might be able to be reduced from 2.0eq per coupling.  Excess DIEA 
could be kept to a minimum, and could eventually be transitioned to 
the much cheaper similar base TEA.  Also lowering coupling times 
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might further drop overall costs when factoring in overall time spent 
on total synthesis. 
 
2.5 Experimental Procedure 
2.5.1 Tert-butyl-2-aminoethylcarbamate 
 
Fig. 2.4 
Ethylenediamine (9.0 eq, 55.6 mL, 831 mmol) was dissolved in THF 
(200 mL).  A solution of Boc2O (1.0 eq, 20 g, 91.6 mmol) in THF (200 
mL) was added dropwise at 0°C overnight.  The resulting solution was 
concentrated, dissolved in DCM (100 mL), and extracted with water 
(3x20 mL).  The water layers were back-extracted with DCM (100 mL), 
and the organic layers were combined and concentrated, leaving a 
yellow oil (14.52 g, 99%). m/z [M+H]+ 161.1. 
TLC conditions: 9:1 methanol: ammonium hydroxide.   
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2.5.2 Tert-butyl (2-(methylsulfonamido)ethyl)carbamate 
 
Fig. 2.5 
Tert-butyl-2-aminoethylcarbamate (1.0 eq, 11.19 g, 69.8 mmol) was 
dissolved in THF (100 mL).  Triethylamine (1.2 eq, 11.68 mL, 83.8 
mmol) was added.  Methanesulfonyl chloride (1.0 eq, 5.41 mL, 69.8 
mmol) was added at room temperature for one hour.  The resulting 
solution was concentrated, dissolved in ethyl acetate (EtOAc, 75 mL), 
and extracted once with brine (10 mL) and twice with water (10 mL).  
The organic layer was concentrated, resulting in an off-white solid 
(15.11 g, 90.8%).   
1H NMR (400 MHz, CDCl3) δ 5.50 (b, 1H), 5.25 (b, 1H), 3.27-3.24 (m, 
2H), 3.22-3.18 (m, 2H), 2.93 (s, 3H), 1.40 (s, 9H).  13C NMR (400 
MHz, CDCl3) ppm 156.74, 79.98, 43.67, 40.80, 40.35, 28.58. 
TLC conditions: 100% ethyl acetate 
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2.5.3 Methyl 2-(N-(2-(tert-
butoxycarbonylamino)ethyl)methylsulfonamido)acetate, Boc-
Linker(OMe) 
 
Fig. 2.6 
Tert-butyl (2-(methylsulfonamido)ethyl)carbamate (1.0 eq, 15.11 g, 
63.4 mmol) was dissolved in THF (100 mL).  A solution of 60% sodium 
hydride in toluene (1.0 eq, 2.54 g, 63.4 mmol) and THF (25 mL) was 
added at 0°C, followed by methyl bromoacetate (1.0 eq, 5.83 mL, 
63.4 mmol), and the solution was stirred for one hour.  The solution 
was quenched with water (10 mL).  The resulting solution was 
concentrated, dissolved in EtOAc (75 mL), and extracted five times 
with water (10 mL).  The organic layer was concentrated, and the 
crude product was recrystallized in 1:1 EtOAc:Hexane (100 mL), 
producing a white solid (14.96 g, 76.0%).   
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1H NMR (400 MHz, CDCl3) δ 5.20 (b, 1H), 4.10 (s, 2H), 3.71 (s, 3H), 
3.35-3.32 (m, 2H), 3.25-3.21 (m, 2H), 2.95 (s, 3H), 1.38 (s, 9H).  13C 
NMR (400 MHz, CDCl3) ppm 170.54, 156.27, 79.72, 52.63, 48.57, 
47.81, 39.79, 38.89, 28.55. 
TLC conditions: 100% ethyl acetate. 
 
2.5.4 Linker(OMe)-Lys(Boc)-NHCbz, Dimer 
 
Fig. 2.7 
Boc-Linker(OMe) (2.00 g, 6.44 mmol) was dissolved in DCM (10 mL).  
Excess trifluoroacetic acid (TFA, 10 mL) was added and allowed to stir 
for 20 mins.  The resulting solution was concentrated, taking special 
care to remove as much excess TFA as possible through multiple DCM 
titurations (3x10 mL), of the resulting residue (2.02 g, 96.5%).  The 
deprotected product (1.0 eq, 2.02 g, 6.22 mmol) was dissolved in dry 
DCM (40 mL) under argon.  DIEA (2.5 eq, 2.57 mL, 16.0 mmol) was 
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added and Z-Lys(Boc)-OH (1.0 eq, 2.37 g, 6.22 mmol) was added.  
Finally, a solution of 50% propanephosphonic anhydride in methylTHF 
purchased from Archimica (®T3P, 2.0 eq, 7.92 mL, 12.4 mmol) was 
added at 0°C and allowed to stir overnight.  The resulting solution was 
quenched with water (10 mL) for 1 hr, then concentrated and 
dissolved in EtOAc (50 mL).  Some crude product precipitated out, and 
was filtered off.  The filtrate was then extracted three times with water 
(10 mL), the organic layer was concentrated, and the resulting crude 
product was combined with the precipitate.  The crude product was 
then recrystallized in ether (10 mL) overnight, producing a white solid 
(1.93 g, 54.6%).  m/z [M+H]+ 573.1.   
1H NMR (400 MHz, CDCl3) δ 7.30-7.26 (m, 5H), 7.00 (b, 3H), 5.74-
5.72 (d, 1H), 5.05 (s, 2H), 4.82 (b, 1H), 4.10 (s, 3H), 3.70 (s, 3H), 
3.36-3.34 (m, 4H), 3.04 (b, 2H), 2.96 (s, 3H), 1.82-1.79 (m, 2H), 
1.62-1.61 (m, 2H), 1.37 (s, 9H), 1.32-1.31 (m, 2H).  13C NMR (400 
MHz, CDCl3) ppm 172.72, 170.51, 156.52, 136.49, 128.70, 128.55, 
128.33, 79.23, 67.19, 55.21, 53.86, 52.69, 48.37, 47.32, 40.12, 
39.61, 37.49, 32.12, 29.72, 28.63, 22.74. 
TLC conditions:  100% ethyl acetate. 
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2.5.5 Linker(OMe)-Lys(Boc)-Leu-NHCbz, Trimer 
 
Fig. 2.8 
Linker(OMe)-Lys(Boc)-NHCbz (1.93 g, 3.38 mmol) was dissolved in 
methanol (100 mL).  Palladium (10%) carbon powder (0.4 g) was 
added, and the solution was placed under H2 pressure (55 psi) 
overnight.  The palladium carbon powder was filtered over 
diatomaceous earth, and the resulting solution was concentrated, 
forming a white solid.  The deprotected product (1.0 eq, 1.48 g, 3.38 
mmol) was dissolved in dry DCM (13 mL) under argon.  DIEA (2.5 eq, 
1.40 mL, 8.44 mmol) was added.  Z-Leu-OH (1.0 eq, 0.896 g, 3.38 
mmol) was added.  Finally, a solution of 50% propanephosphonic 
anhydride in methylTHF (®T3P, 2.0 eq, 4.30 mL, 6.75 mmol) was 
added at 0°C and allowed to stir overnight.  The resulting solution was 
quenched with water (5 mL) for 1 hr, then concentrated and dissolved 
in EtOAc (50 mL).  Some crude product precipitated out, and was 
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filtered off.  The filtrate was then extracted three times with water (10 
mL), the organic layer was concentrated, and the resulting crude 
product was combined with the precipitate.  The crude product was 
then recrystallized in ether (10 mL) overnight, producing a white solid 
(1.99 g, 86.3%).  m/z [M+H]+ 686.1.   
1H NMR (400 MHz, cdcl3) δ 7.36 – 7.30 (m, 4H), 6.95 (s, 1H), 6.74 (d, 
J = 7.8, 1H), 5.40 (d, J = 6.3, 0H), 5.11 (s, 2H), 4.82 (s, 1H), 4.39 (t, 
J = 14.9, 1H), 4.13 (s, 2H), 3.75 (d, J = 5.5, 3H), 3.47 (dd, J = 13.9, 
7.0, 1H), 3.36 (d, J = 8.1, 3H), 3.05 (d, J = 6.0, 2H), 2.97 (s, 3H), 
1.41 (s, 9H), 1.29 (d, J = 6.1, 2H), 1.19 (d, J = 7.0, 0H), 0.93 (d, J = 
4.3, 6H).  13C NMR (101 MHz, cdcl3) δ 172.68, 172.08, 170.53, 
136.35, 128.77, 128.25, 67.39, 54.19, 53.14, 52.69, 48.18, 47.30, 
41.02, 40.36, 39.72, 37.18, 31.68, 29.49, 28.66, 24.93, 23.29, 22.84, 
21.87. 
TLC conditions: 100% ethyl acetate. 
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2.5.6 Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-NHCbz, Tetramer 
 
Fig. 2.9 
Linker(OMe)-Lys(Boc)-Leu-NHCbz (1.99 g, 2.91 mmol) was dissolved 
in methanol (100 mL).  Palladium (10%) carbon powder (0.4 g) was 
added, and the solution was placed under H2 pressure (55 psi) 
overnight.  The palladium carbon powder was filtered over 
diatomaceous earth, and the resulting solution was concentrated, 
forming a white solid.  The deprotected product (1.0 eq, 1.60 g, 2.91 
mmol) was dissolved in dry DCM (10 mL) under argon.  DIEA (2.5 eq, 
1.20 mL, 7.27 mmol) was added.  Z-Lys(Boc)-OH (1.0 eq, 1.11 g, 
2.91 mmol) was added.  Finally, a solution of 50% propanephosphonic 
anhydride in methylTHF (®T3P, 2.0 eq, 3.70 mL, 5.81 mmol) was 
added at 0°C and allowed to stir overnight.  The resulting solution was 
quenched with water (5 mL) for 1 hr, then concentrated and dissolved 
in EtOAc (50 mL).  Some crude product precipitated out, and was 
filtered off.  The filtrate was then extracted three times with water (10 
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mL), the organic layer was concentrated, and the resulting crude 
product was combined with the precipitate.  The crude product was 
then recrystallized in ether (10 mL) overnight, producing a white solid 
(2.19 g, 82.7%).  m/z [M+H]+ 914.3.   
1H NMR (400 MHz, cdcl3) δ 7.32 (d, J = 14.9, 5H), 7.07 (s, 1H), 6.73 
(s, 0H), 6.12 (d, J = 17.4, 0H), 5.12 – 5.03 (m, 2H), 4.84 (s, 1H), 
4.71 (s, 6H), 4.16 (s, 2H), 3.75 (d, J = 6.1, 3H), 3.51 – 3.43 (m, 1H), 
3.40 (d, J = 4.8, 3H), 3.15 – 3.02 (m, 4H), 3.00 (s, 3H), 1.39 (d, J = 
10.4, 18H), 1.26 – 1.16 (m, 2H), 0.91 (dt, J = 20.0, 10.0, 6H).  13C 
NMR (101 MHz, cdcl3) δ 170.63, 128.88, 105.10, 52.57, 47.18, 39.70, 
28.71, 25.15, 23.33, 21.82. 
TLC conditions: 100% ethyl acetate. 
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2.5.7 Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-Leu-NHCbz, 
Pentamer 
 
Fig. 2.10 
Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-NHCbz (2.19 g, 2.40 mmol) was 
dissolved in methanol (100 mL).  Palladium (10%) carbon powder (0.4 
g) was added, and the solution was placed under H2 pressure (55 psi) 
overnight.  The palladium carbon powder was filtered over 
diatomaceous earth, and the resulting solution was concentrated, 
forming a white solid.  The deprotected product (1.0 eq, 1.87 g, 2.40 
mmol) was dissolved in dry DCM (15 mL) under argon.  DIEA (2.5 eq, 
1.04 mL, 6.00 mmol) was added.  Z-Leu- OH (1.0 eq, 0.638 g, 2.40 
mmol) was added.  Finally, a solution of 50% propanephosphonic 
anhydride in methylTHF (®T3P, 2.0 eq, 3.06 mL, 4.79 mmol) was 
added at 0°C and allowed to stir overnight.  The resulting solution was 
quenched with water (5 mL) for 1 hr, then concentrated and dissolved 
in EtOAc (50 mL).  Some crude product precipitated out, and was 
filtered off.  The filtrate was then extracted three times with water (10 
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mL), the organic layer was concentrated, and the resulting crude 
product was combined with the precipitate.  The crude product was 
then recrystallized in ether (10 mL) overnight, producing a white solid 
(1.83 g, 74.5%).  m/z [M+H]+ 1027.3. 
TLC conditions: 100% ethyl acetate. 
 
2.5.8  
*Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-Leu-Lys(Boc)-NHCbz, 
cHYD1 Non-Recognition Strand (cHYD1 NRS) 
 
Fig. 2.11 
Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-Leu-NHCbz  (1.83 g, 1.78 mmol) 
was dissolved in methanol (100 mL).  Palladium (10%) carbon powder 
(0.4 g) was added, and the solution was placed under H2 pressure (55 
psi) overnight.  The palladium carbon powder was filtered over 
diatomaceous earth, and the resulting solution was concentrated, 
forming a white solid.  The deprotected product (1.0 eq, 1.59 g, 1.78 
mmol) was dissolved in dry DCM (15 mL) under argon.  DIEA (2.5 eq, 
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0.736 mL, 4.45 mmol) was added.  Z-Lys(Boc)-OH (1.0 eq, 0.678 g, 
1.78 mmol) was added.  Finally, a solution of 50% propanephosphonic 
anhydride in methylTHF (®T3P, 2.0 eq, 2.27 mL, 3.56 mmol) was 
added at 0°C and allowed to stir overnight.  The resulting solution was 
quenched with water (5 mL) for 1 hr, then concentrated and dissolved 
in EtOAc (50 mL).  Some crude product precipitated out, and was 
filtered off.  The filtrate was then extracted three times with water (10 
mL), the organic layer was concentrated, and the resulting crude 
product was combined with the precipitate.  The crude product was 
then recrystallized in ether (10 mL) overnight, producing a white solid 
(2.00 g, 89.5%). m/z [M+Na]+ 1277.529. 
TLC conditions: 100% ethyl acetate. 
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CHAPTER THREE: 
DEVELOPMENT OF A NOVEL hGH ANTAGONIST AND AGONIST 
 
3.1 Introduction 
Human growth hormone (hGH) is involved in many somatotropic 
and lactogenic activities, as well as a host of cellular metabolic 
mechanisms.  Deficiencies of hGH can lead to reduction in lean body 
mass, decreased skeletal and cardiac muscle mass and strength, 
reduction of bone density, and in extreme cases, dwarfism.  Over-
expression can have equally devastating effects, possibly leading to 
acromegaly, pituitary tumors, and certain type 1 diabetic conditions.  
Produced in the pituitary gland, hGH is a 191 residue, 22kDA protein, 
consisting of four distinct alpha helices ordered in an “up-up-down-
down” conformation.  Two mini-helices located in the loop between 
helix 1 and 2 help in molecular stabilization and binding. 
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Fig 3.1 PDB of 1HGU (1) 
 
While studies have shown hGH to signal a variety of receptors 
(2), its evolutionary purpose is to signal the human growth hormone 
receptor (hGHR).  hGHR is a member of sub-class 1 of the cytokine 
receptor family(3), involving JAK2 activation via phosphorylation of the 
kinase domain of JAK2 once hGHR is bound by the hormone, leading to 
further signaling and the resultant biological effect (4, 5).  It is a single 
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transmembrane protein, consisting of 246 residues in its extracellular 
domain (ECD).  Signaling of the hGHR involves ligand-driven 
homodimerization in a step-wise fashion.  hGH binds to the ECD of one 
hGHR at a region affectionately known as Site 1, involving portions of 
helix 4, as well as parts of the two mini-helices between helix 1 and 2.  
This hGH:hGHR complex then binds to a second hGHR in a region 
known as Site 2 via portions of helix 1 and 3 of the hGH molecule and 
a similar region of hGHR to its Site 1 binding region (6, 7).  Site 1 
binding has a much higher affinity than Site 2 binding, and involves a 
much larger surface area (1300Å2 and 900Å2, respectively).  This 1:2 
(hGHR:hGH:hGHR) complex induces conformational changes within 
the given hGHRs, allowing binding between the two receptors, which 
ultimately leads to intracellular signaling (8, 9, 10). Interestingly 
enough, Wells’ group (11) showed that binding was due to rate of 
dissociation of the hormone to the receptor, rather than association. 
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Scheme 3.1 Schematic of hGHR dimerization (12) 
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Fig 3.2 PDB of hGHR 1 (red), hGHR2 (green), and hGH (white) (13) 
 
Due to the homodimerization complex, and the fact that Site 1 
binding has a higher affinity, disruption of the Site 2 binding region 
has been the focus in leads towards antagonism of hGHR.  A single site 
mutation of hGH (G120R) proved to disrupt Site 2 binding, creating a 
useful antagonist which has been used as the basis for most hGH 
antagonist drug discoveries (14).  Ultimately, increasing Site 1 binding 
affinity in addition to disruption of Site 2 binding has led to “super-
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antagonism” of hGHR, which has led to the drug Pegvisomant (15, 16, 
17). 
Agonism of hGHR has been limited due to the asymmetrical 
properties of hGH and its binding to the separate hGHRs.  Monoclonal 
antibodies have been used with limited success (18).  Activity has 
been shown in studies, but not to the degree that wild-type hGH 
shows.  Currently, only recombinant hGH molecules such as 
Genotropin® (Pfizer) are on the market for drug administration, 
showing a glaring need for smaller, more biologically effective 
agonists. 
 
3.2 Specific Aim 
 The specific aim of this proposal is to develop an hGH agonist.  
In order to do so, the first step is to analyze the high affinity Site 1 
binding region.  Clackson, et al, (19) have shown that only a few 
residues located in a small hydrophobic area (the “hot spot”) account 
for more than 90% of the binding free energy.  Two tryptophan 
residues (W104 and W169) of the hGHR are involved in this “hot 
spot”.  They are located 4.54Å apart, sitting in a stacked formation.   
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Fig 3.3 PDB of 1:1 hGH (white):hGHR (red).  W104 and W169 of hGHR are 
highlighted in yellow, representing the “hot spot”.  R64, K172, and T175 are 
highlighted in green (20). 
 
 
 Closer inspection of hGH binding shows that three residues (R64, 
K172, and T175) of the hormone create the binding of the ligand to 
these two tryptophan residues.  R64 of hGH packs on top of W169 of 
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hGHR via Van der Waals forces between the carbon skeleton of the 
side-chain of R64 and the aromatic ring of W169.  Some evidence 
suggests R64’s guanido group interacts with D164 and E44 of hGHR.  
K172 of hGH packs on top of W104 of hGHR similar to the 
R64hGH:W169hGHR interaction.  The γ-CH3 group of T175 of hGH sits 
in the same plane as the aromatic ring of W104 of hGHR, creating a 
Van der Waals force.  There is some suggestion that the oxygen atom 
of the hydroxyl group of T175 is a hydrogen bond acceptor to R43 of 
hGHR, too.   
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Fig 3.4 R64 of hGH (green) showing alkyl-aromatic stacking with W169 of hGHR 
(yellow).   
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Fig 3.5 K172 of hGH (green) showing alkyl-aromatic stacking with W104 of hGHR 
(yellow).   
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Fig 3.6 γ-CH3 of T175 of hGH (green) in the same plane as W104 of hGHR (yellow). 
 
 Other residues involved in binding energy (I103, I105, P106, 
D126, and I165 of hGHR, and L54, P61, F176, and R178 of hGH, 
respectively) are actually intramolecular interactions for stabilization of 
hGHR and hGH, respectively, allowing the binding to take place.  The 
distance between the α-carbons of K172 and T175 of hGH is 5.178Å, 
while the distance between T175 and R64 of hGH is 9.979Å.  The angle 
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created from K172:T175:R64 is 94.1°.  Ideally, using a peptide 
scaffold mimicking these distances and angles would lead to a 
compound which binds to the receptor.   
 Interestingly enough, a cyclized peptide scaffold combing 
Robinson’s D-Pro/L-Pro beta-hairpin turn (21) with a 
methylsulfonamido aminoethyl glycine residue on the other turn end 
linking two five-residue strands (developed by the McLaughlin group) 
produced almost identical distances and angles separating the α-
carbons of residues 2, 5, and 6 (residues 2 and 5 are 9.729Å apart, 
residues 5 and 6 are 5.167Å apart, and an angle of R2:R5:R6 is 90.9° 
is created), while aligning the residues in the correct conformation. 
 
Fig 3.7 Cyclized peptidic scaffold originally used to mimic hGH functional epitope 
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 Logic would dictate substituting an arginine residue for R2, a 
threonine residue for R5, and a lysine residue for R6, therefore 
mimicking the functional epitope of the native hGH molecule.  
Unfortunately, due to a “hump” in the surface area of the binding 
region, the resulting molecule cannot bind effectively, as modeling 
projections show it protruding through the surface of the binding 
region, and the resulting minimization confirms binding cannot be 
attained.   
 
Fig 3.8 Surface area showing “hump” around the “hot spot”, W104 and W169 
(yellow).   
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 Using this scaffold, however, minimization shows there to be 
enough of a natural curvature within the molecule to fit around the 
surface area “hump”, with residues 3, 5, 6, and 8 being in position to 
be directed around the two tryptophan residues of the receptor.  When 
substituting R3 with serine, R5 with lysine, R6 with leucine, and R8 
with lysine, minimization and modeling shows binding of the molecule 
to the receptor in a similar fashion to hGH binding. 
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Fig 3.9 Proposed cyclized peptide molecule (grey) bound to hGHR (red). W104 and 
W169 of hGHR (yellow) are shown. 
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 The hydrogen of the hydroxyl-group of S3 forms a hydrogen 
bond with the main-chain carbonyl oxygen of G168 of the receptor 
(directly next to W169).  The δ-methyl groups of L6 are positioned in 
the same plane as both tryptophan rings of the receptor, suggesting 
similar binding as T175 of hGH with some possible additive effects 
(another methyl group joining in with Van der Waals forces to W169 
along with the aforementioned W104).  Most importantly, K5 and K8 
show alkyl-aromatic stacking with W169 and W104, respectively, 
mimicking hGH binding.  One hydrogen of the amine group on the 
side-chain of K5 also forms a hydrogen bond with the carbonyl-oxygen 
of E44 of the receptor, further strengthening binding, and matching a 
previously suggested (but unconfirmed) interaction of the guanido 
groups of R64 of hGH to E44 of hGHR.   
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Fig 3.10 K8 (grey) showing alkyl-aromatic stacking on W104 of hGHR (yellow). 
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Fig 3.11 K5 (grey) showing alkyl-aromatic stacking on W169 of hGHR (yellow). 
 
 There are also a couple unexpected hydrogen-bonding regions 
somewhat downfield of the “hot spot”.  The carbonyl-oxygen of the 
main-chain of the methylsulfonamido aminoethyl glycine forms a 
hydrogen-bond with the hydrogen of the amino group on the side 
chain of R217 of the receptor, while one of the carbonyl-oxygen’s of 
the sulfono-group of the same residue forms a hydrogen-bond with the 
hydrogen of the amino group on the side chain of N218 of the 
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receptor.  This could lead to further stabilization of the binding of the 
molecule.   
 
 
Fig 3.12 Hydrogen-bonding shown (in yellow) between proposed cyclized peptide 
molecule and hGHR. 
 
 
 To dimerize hGHR, thus creating biological activity, the first 
thought would be to study Site 2 binding.  However, recent studies 
have shown that dimerized antagonists which have an affinity for Site 
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1 but no affinity for Site 2 have shown hGHR activity (22, 23).  This 
suggests two Site 1 binding regions can dimerize the receptors 
effectively.   
 
Fig 3.13 Comparison of hGHR binding between hormone (A) and dimerized 
antagonists (B) (23). 
 
 The idea then would be to link two Site 1 peptidic mimics 
together, preferably with the correct length.  This can be accomplished 
by substituting R9 of the molecule with lysine, as its side-chain 
extends away from the receptor at virtually a 90° angle.  A subsequent 
polyethylene glycol (PEG) segment (24) can be attached to the side-
chain amine, linking two concurrent Site 1 peptidic mimics together.  
In hGH binding, the dimerized receptors have a distance of roughly 
22Å between Site 1 binding regions.   The distance from the side-chain 
amine of K9 to the Site 1 binding region is roughly 12Å.  One PEG 
segment is 5Å, therefore only one is needed to link the two mimics, 
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giving roughly a 29Å distance between binding regions.  This distance 
could be minimized further if needed, possibly by substituting cysteine 
in the R9 position.   
 
Fig 3.14 Proposed peptidic molecule including linker. 
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Fig 3.15 Rendering of proposed molecule dimerizing hGHR. 
 
 
3.3 Synthesis 
 Synthesizing the molecule would be done through typical Fmoc 
solid-phase synthesis.  Any residue of the scaffold can be initially 
downloaded to Wang resin, although to make synthesis easier, 
commercially available Fmoc-Lys(Boc)-Wang Resin would be used.  K9 
would need an allyl-protecting group on the side-chain, rather than a 
Boc group.  Synthesis of the linear chain would include Fmoc-
deprotection via 20% Piperidine/2%DBU in DMF, followed by residue 
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coupling using HCTU/NMM in DMF for activation purposes.  The 
resulting linear chain would be cleaved from the resin using 20% 
trifluoroethanol in DCM (so as to not cleave the allyl and Boc-
protecting groups from the side chains), and then cyclization would be 
performed via another coupling step using HCTU/NMM in DMF.  The 
allyl-protecting group of K9 would then be cleaved using 2 equivalents 
of Pd(PPh3)4 in 37:2:1 CHCl3:Acetic Acid:NMM.  The PEG monomer 
would be coupled to the molecule next through another coupling using 
2 equivalents of the peptide molecule, again via HCTU/NMM in DMF.  
Finally, the resulting dimerized peptide would be subjected to 95:2:2:1 
TFA:Water:Anisole:EDT for cleavage and scavenging of all protecting 
groups. 
 
3.4 Chemical Evaluation 
 To determine the purity of the resultant hGH agonist, high-
performance liquid chromatography (HPLC) would be used, allowing a 
gradient from 5% to 90% acetonitrile as the solution phase.  Matrix-
assisted laser desorption ionization via a time-of-flight tube for mass 
spectrometry (MALDI-TOF MS) would be used for molecular weight 
verification.  NMR and CD analysis could be used, if necessary, to 
study structural integrity. 
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3.5 Biological Evaluation 
 For comparison purposes, hGH and G120R (antagonist) cDNAs 
would be cloned via the bacterial expression vector pET22b, and the 
subsequent ligands would be purified.  Frank’s group (23, 25) reports 
the development of a line of cells named “C14 cells” which would be 
used to determine signal transduction of the bound GHR.  As noted, 
they “are the result of a stable transfection of GHR- and JAK2-deficient 
human fibrosarcoma cell line γ2A with the wild-type rabbit GHR and 
mouse JAK2.”  C14 cells would be treated with equivalent molar 
concentrations of each ligand, SDS-PAGE would be used for resolution, 
and immunoblotting would be conducted using anti-GHR (to show 
downfield GHR conformational change) (26), anti-JAK2 and anti-
phospho-JAK2 (anti-pJAK2, to determine JAK2 activation via tyrosine-
phosphorylation), and anti-STAT5 and anti-phospho-STAT5 (anti-
pSTAT5, to determine STAT5 activation via tyrosine-phosphorylation).  
Densitometry can be used to determine relative potency of the 
signaling at different concentrations of the ligand. 
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3.6 Optimization 
 After careful consideration, it was determined that 5-atom turn 
promoter opposite of the D-Pro/L-Pro turn in the proposed molecule 
would be extremely difficult to synthesize.  With a known synthetic 
protocol already in place for the similar 6-atom turn promoter (as 
referenced in Chapter 2), this promoter was used, giving the peptidic 
scaffold represented in Fig 3.16. 
 
Fig 3.16 New peptidic scaffold introducing 6-atom turn promoter 
 
 Using the molecular modeling software MacroModel in Maestro 
v9.2 by Schrödinger, the extra methylene group in the new peptide 
proved to be very beneficial.  In comparing the new SKLK peptide to 
its older counterpart, the new peptide included six to ten hydrogen-
bonds with the given receptor, none of which involved the new 6-atom 
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turn promoter, whereas the older peptide only included four hydrogen-
bonds with the receptor, two of which involved the 5-atom turn 
promoter.  The older peptide had a relatively poor conformation, 
involving only one intramolecular hydrogen-bond, and included no 
secondary structure recognition by the software.  In contrast, the 
newer peptide had a very good conformation, preserving all six 
intramolecular hydrogen bonds, and showing a beta-turn secondary 
structure, the desired structure needed for this particular protein-
protein interaction between peptide and receptor.  The new peptide 
still sustained all the same Site 1 binding as the old peptide as well. 
 
3.6.1 Peptide Docking Procedure Overview 
 In docking the peptides via MacroModel, the PDB 3HHR, Fig 3.2, 
was used.  Priming was used to fill the missing residues, one histidine 
and one threonine away from the Site 1 binding region of each 
respective receptor.  Once the hormone was removed from the dimer 
structure, Sitemap could not locate the convex hormone binding site of 
Site 1, involving W104 and W169.  Only binding of the stem regions of 
the receptors to each other was recognized, which represents the final 
dimerization of the receptors leading towards the biological effect 
within the cell.  This lack of recognition of the Site 1 binding site led to 
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the manual placement of single cyclized peptides on both receptors.  
Minimization and conformational searches were then performed with 
the receptors rendered frozen.  Placement of the peptides in places 
other than the Site 1 binding site, as well as other peptides not 
capable of binding to Site 1, floated away after minimizations, as 
represented by Fig 3.17, while those that did bind stayed in the Site 1 
binding region, as represented by Fig 3.18. 
 
Fig 3.17 Peptide not binding to receptor during minimization 
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Fig 3.18 Peptide binding to receptor after minimization 
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3.6.2 Linker Optimization 
 In the proposed molecule, one PEG unit was determined to be of 
use as a linker between the two cyclized peptides due to the relative 
correct distance between Site 1 binding sites of the dimerized 
molecule.   
 
Fig 3.19 One polyethylene glycol unit, PEG 
 
After some consideration, possible linker derivatives were 
explored.  One particular linker, 5-aminoisophthalic acid, was thought 
to be of more use due to having the same relative distance as PEG yet 
allowing for a more rigid conformation given its benzene ring.  This 
should theoretically allow for less free movement in space, allowing 
the dimerized molecule to be in a more correct position for dual Site 1 
bindings and ultimately saving free energy within the given system.  
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Fig 3.20 5-aminoisophthalic acid, APA 
 
 A two-unit PEG system was also explored, mainly as a way to 
see if the excess distance would be a factor in linker development. 
 
Fig 3.21 Two polyethylene glycol units, PEG2 
 
3.6.2.1 Linker Docking Procedure Overview 
 In each of the three linker-peptide complexes, the same 
procedure was used via MacroModel.  The peptides were created with 
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both receptors in place, and the linkers were then attached via the 
side-chain amine of K9 with the appropriate free carboxylates of the 
corresponding linkers.  Minimization was then performed on the linkers 
only, with the receptors and peptides frozen.  Once this was done, 
minimization was then performed with the di-cyclized peptides with 
the receptors frozen.  A conformational search was then run on each of 
the di-cyclized peptides, again with their respective receptors frozen.   
 
Table 3.1 Peptide-Only Conformational Energies 
Linker Potential Energy (kJ/mol) 
APA -21998 
PEG -21042 
PEG2 -20499 
 
A conformational search was then run with the di-cyclic 
peptide/dimerized receptor complex in large-scale low mode.  Finally, 
a minimization of each entire complex was performed.   
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Table 3.2 Full Complex Minimization Energies 
Linker ΔG binding (kJ/mol) 
APA -582,739.217 
PEG -557,469.042 
PEG2 -555,214.104 
 
 Interestingly enough, all three linkers seemed to be of relative 
similar use, with no significant differences between them in their 
respective total energies.  This can also be seen in Fig 3.22, showing 
the overlay of each of the di-cyclized peptides and their respective 
linkers. 
 
Fig 3.22 Overlay of di-cyclic peptides 
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 When compared to the binding of the hormone, the respective 
dimerized complexes also share very similar characteristics.  Fig 3.23 
shows this perfectly, with the overlay of all four complexes and the 
hormone being removed for aesthetic purposes. 
 
Fig 3.23 Overlay of all with PDB 3HHR 
 
3.6.3 APA Example 
 Docking of the di-cyclized peptide with the APA linker is shown in 
Fig 3.24 via the “side view” and in Fig 3.25 via the “overhead view”.  
This shows the secondary beta-turn structure being conserved after 
binding with and dimerizing the receptors. 
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Fig 3.24 “Side view” of di-cyclized peptide with APA linker 
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Fig 3.25 “Overhead view” of di-cyclized peptide with APA linker 
 
 The hydrogen-bonding between peptides and their respective 
receptors are conserved as noted in Section 3.6.  There are ten 
hydrogen-bonds with the “major” receptor and six hydrogen-bonds 
with the “minor” receptor, as noted in Table 3.3 and 3.4, respectively.   
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Table 3.3 “Major” Receptor Hydrogen-Bonding (bb = backbone) 
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Table 3.4 “Minor” Receptor Hydrogen-Bonding (bb = backbone) 
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3.6.4 APA Synthesis and Linkage 
 
Scheme 3.2 Schematic of APA Synthesis and Linkage 
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 The starting material that leads to the eventual synthesis of APA 
and its subsequent linkage is the commercially available 5-
nitroisophthalic acid.  After hydrogenation of the starting material, 5-
aminoisophthalic acid was formed.  The free amine should be 
protected, which was done via placement of the Boc group in the 
presence of TEA in methanol.   
 
3.6.4.1 Lysine Derivative Synthesis 
 
Scheme 3.3 Fmoc-Lys-OAllyl Synthesis 
 
 In order to couple the APA linker to the side-chain amine of K9, 
the lysine derivative must first be synthesized.  The starting material 
used was the commercially available Fmoc-Lys(Boc)-OH.  This was first 
treated with cesium carbonate in the presence of methanol in order to 
promote O-alkylation, which was then performed via the introduction 
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of allyl bromide in the presence of DMF.  The pure product was then 
treated with methanesulfonic acid in DCM, allowing for selective 
deprotection of the side-chain amine.  Originally, TFA was used for 
deprotection.  However, residual TFA caused coupling problems, 
capping off the free amine when activator was introduced.  This led to 
the desire to use methanesulfonic acid as an alternative deprotection 
source.  DIEA was then used to neutralize the solution, allowing for 
coupling to take place. 
 
3.6.4.2 Coupling 
 The coupling of the APA linker to the now free amine of the side-
chain of the main-chain protected K9 was then performed.  This was 
done with DIEA and ®T3P in the presence of THF. 
 
3.7 Future Considerations 
 Some future considerations involving the development of 
antagonist and agonist hGH mimics could include a library of different 
linkers.  Ideally, these linkers would be of the same distance as PEG, 
as that would mimic the closest length between Site 1 binding sites.  
However, as mentioned above with the PEG2 results, this may not be 
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necessary.  Linker exploration could involve a host of different lengths 
as well as rigidity.  Linker synthesis could and should be optimized as 
well, as the coupling step with the K9 residue at the moment is a 
troubling step.   
 The other major consideration could and should be the inclusion 
of an entire combinatorial peptidic library developed around the lead 
scaffold.  This would include both the “important” residues used for 
binding as well as the “non-important” residues currently being 
represented by the use of alanine, and a myriad of different turn 
promoters.  This could be done computationally or via quick trial-and-
error through solid phase synthesis and biological testing.   
 
3.8 Experimental Procedures 
3.8.1 Antagonist Synthesis 
 The antagonist was developed through solid phase peptide 
synthesis on Protein Technologies’ automated 12-vessel synthesizer 
The Symphony®.  Fmoc-Lys-OAllyl was attached to 2-chlorotrityl resin 
by the side-chain free amine.  Each amino acid synthesis step included 
an NMP wash (3 times at 30 second intervals), Fmoc deprotection via 
20% Piperidine/2% DBU in DMF (1 loop volume, 1.25 mL, at 2:30), 
NMP wash (3 times at 30 second invervals), introduction of the amino 
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acid (1 loop volume, 1.25 mL) and coupling agent HCTU (1 eq) and 
NMM (4 eq) in DMF (1 loop volume, 1.25 mL, at 5:00 twice through), 
followed by NMP wash (3 times at 30 second intervals).   
When the linear chain was finished, cyclization was performed 
on-resin.  Allyl deprotection was performed via 2 equivalents of 
Pd(PPh3)4 in 37:2:1 CHCl3:Acetic Acid:NMM in NMP (90 minutes).  
Following NMP washes (3 times at 30 second intervals), HCTU (1 eq) 
and NMM (4 eq) in NMP (60 minutes) are used to couple the N-
terminal and C-terminal amino acids.  After successful cyclization, the 
peptide and subsequent side-chain protecting groups were cleaved 
using 95:2:2:1 TFA:Water:Anisole:EDT (60 minutes).   
 
 
 
 
 
 
 
 
105 
 
3.8.2 Agonist Synthesis 
3.8.2.1 5-Aminoisophthalic Acid 
 
Fig 3.26 
Commercially available 5-nitroisophthalic acid (4.37 g, 20.70 mmol) 
was dissolved in methanol (100 mL).  Palladium (10%) carbon powder 
(0.4 g) was added, and the solution was placed under H2 pressure (55 
psi) overnight.  The palladium carbon powder was filtered over 
diatomaceous earth, and the resulting solution was concentrated, 
forming a white solid (3.75 g, quant).   
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3.8.2.2 5-((tert-butoxycarbonyl)amino)isophthalic acid 
 
Fig 3.27 
5-aminoisophthalic acid (1.0 eq, 2.28 g, 12.6 mmol) was dissolved in 
methanol (40 mL).  TEA (3.0 eq, 5.25 mL, 37.7 mmol) was added, 
followed by Boc2O (1.1 eq, 3.02 g, 13.8 mmol).  The reaction was 
stirred overnight at room temperature.  Concentrated HCl (10 mL) was 
added, and the milky white solution was then poured over stirred 
water (400 mL).  The precipitate was filtered off, producing a pure 
white solid product (2.02g, 57.1%). m/z [M+Na]+ 304.0. 
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3.8.2.3 Fmoc-Lys(Boc)-OAllyl 
 
Fig 3.28 
Commercially available Fmoc-Lys(Boc)-OH (1.0 eq, 5.0 g, 10.7 mmol) 
was dissolved in methanol (15 mL).  Cesium carbonate (0.5 eq, 1.74 
g, 5.34 mmol) was added, and the mixture was stirred at 0°C for 10 
minutes.  The reaction was concentrated and left under high vacuum 
for 15 minutes.  The product was dissolved in DMF (20 mL), and allyl 
bromide (5.0 eq, 4.62 mL, 53.4 mmol) was added.  The reaction was 
stirred overnight at room temperature.  After concentration, the 
product was recrystallized in a 9:1 hexane: ethyl acetate mixture, 
producing a white solid precipitate (5.25 g, 96.7%). 
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3.8.2.4 hGH Linker 
 
Fig 3.29 
Fmoc-Lys(Boc)-OAllyl (1.0 eq, 0.503 g, 0.99 mmol) was dissolved in 
dry DCM (8 mL).  Methanesulfonic acid (4.0 eq, 0.257 mL, 3.96 mmol) 
was added, and the reaction was stirred at room temperature for 20 
minutes.  After confirmation of Boc deprotection via TLC (100% ethyl 
acetate) DIEA (5.0 eq, 0.812 mL, 4.94 mmol) was added to the stirred 
mixture.  5-((tert-butoxycarbonyl)amino)isophthalic acid (0.3 eq, 
0.083 g, 0.30 mmol) was added.  More DIEA (1.0 eq, 0.163 mL, 0.99 
mmol) was added.  Finally, a solution of 50% propanephosphonic 
anhydride in methylTHF purchased from Archimica (®T3P, 0.6 eq, 0.38 
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mL, 0.59 mmol) was added at 0°C, and the mixture was allowed to stir 
overnight.  The resulting solution was quenched with water (5 mL), 
concentrated, and dissolved in EtOAc (20 mL).  The organic layer was 
extracted three times with water (5 mL), dried over sodium sulfate, 
and concentrated.  The crude product was purified via 
chromatography, with the product eluting at a ratio of 1:1 
hexane:ethyl acetate, producing a clear solid (0.300 g, 57.1%).  m/z 
[M+H]+ 1062.4. 
 
3.8.2.5 Agonist 
 The agonist was developed through solid phase peptide 
synthesis on Protein Technologies’ automated 12-vessel synthesizer 
The Symphony®.  hGH linker was first deprotected with TFA (10 eq) in 
DCM (5 mL).  The free amine was then attached to 2-chlorotrityl resin.  
Each amino acid synthesis step included an NMP wash (3 times at 30 
second intervals), Fmoc deprotection via 20% Piperidine/2% DBU in 
DMF (1 loop volume, 1.25 mL, at 5 minutes), NMP wash (3 times at 30 
second invervals), introduction of the amino acid (2 loop volumes, 
2.50 mL) and coupling agent HCTU (1 eq) and NMM (4 eq) in DMF (2 
loop volumes, 2.50 mL, at 30 minutes twice through), followed by NMP 
wash (3 times at 30 second intervals).   
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 When the linear chains were finished, cyclization was performed 
on-resin.  Allyl deprotection was performed via 4 equivalents of 
Pd(PPh3)4 in 37:2:1 CHCl3:Acetic Acid:NMM in NMP (90 minutes).  
Following NMP washes (3 times at 30 second intervals), HCTU (2 eq) 
and NMM (8 eq) in NMP (60 minutes) are used to couple the N-
terminal and C-terminal amino acids.  After cyclization, the peptide 
and subsequent side-chain protecting groups were cleaved using 
95:2:2:1 TFA:Water:Anisole:EDT (60 minutes).  
 Unfortunately, this synthesis failed.  An alternative route was 
then explored.  More antagonist was synthesized as mentioned in 
Section 3.8.1, with the side-chain amines of the lysines at positions 5 
and 8 being protected with a Cbz group, producing a compound 
referred to as Antagonist-Z.  Antagonist-Z (2.0 eq, 11.24 mg, 7.11 
µmol) was dissolved in THF (1 mL).  DIEA (5.0 eq, 2.94 µL, 17.8 µmol) 
was added.  5-((tert-butoxycarbonyl)amino)isophthalic acid (1.0 eq, 
1.00 mg, 3.56 µmol) was added.  Finally, a solution of 50% 
propanephosphonic anhydride in methylTHF purchased from Archimica 
(®T3P, 3.0 eq, 6.79 µL, 10.67 µmol) was added, and the reaction was 
stirred at room temperature for 3 days.  After workup and 
deprotection, however, we were unable to observe the product via 
mass spectrometry.   
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APPENDIX A:  SELECTED 1H AND 13C NMR SPECTRA 
 
Tert-butyl (2-(methylsulfonamido)ethyl)carbamate 1H NMR 
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Tert-butyl (2-(methylsulfonamido)ethyl)carbamate 13C NMR 
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Methyl 2-(N-(2-(tert-
butoxycarbonylamino)ethyl)methylsulfonamido)acetate, Boc-
Linker(OMe) 1H NMR 
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Methyl 2-(N-(2-(tert-
butoxycarbonylamino)ethyl)methylsulfonamido)acetate, Boc-
Linker(OMe) 13C NMR 
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Linker(OMe)-Lys(Boc)-NHCbz, Dimer 1H NMR 
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Linker(OMe)-Lys(Boc)-NHCbz, Dimer 13C NMR 
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Linker(OMe)-Lys(Boc)-Leu-NHCbz, Trimer 1H NMR 
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Linker(OMe)-Lys(Boc)-Leu-NHCbz, Trimer 13C NMR 
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Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-NHCbz, Tetramer 1H NMR 
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Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-NHCbz, Tetramer 13C NMR 
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APPENDIX B: SELECTED MASS SPECTRA 
 
Tert-butyl-2-aminoethylcarbamate MS Data 
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Tert-butyl (2-(methylsulfonamido)ethyl)carbamate MS Data 
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Linker(OMe)-Lys(Boc)-NHCbz, Dimer MS Data 
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Linker(OMe)-Lys(Boc)-Leu-NHCbz, Trimer MS Data 
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Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-NHCbz, Tetramer MS Data 
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Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-Leu-NHCbz, Pentamer MS 
Data 
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Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-Leu-Lys(Boc)-NHCbz, 
cHYD1 Non-Recognition Strand (cHYD1 NRS) MS Data 
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5-Aminoisophthalic Acid MS Data 
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5-((tert-butoxycarbonyl)amino)isophthalic acid MS Data 
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Fmoc-Lys(Boc)-OAllyl MS Data 
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hGH Linker MS Data 
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APPENDIX C: LIST OF ABBREVIATIONS 
 
Ala = Alanine 
APA = 5-Aminoisophthalic Acid 
Arg = Arginine 
Asn = Asparagine 
Asp = Aspartic Acid 
ATP = Adenosine Triphosphate 
Boc = tert-Butyloxycarbonyl 
Boc2O = Di-tert-butyl Dicarbonate 
CAM-DR = Cell Adhesion Mediated Drug Resistance 
Cbz = Carboxybenzyl 
CD = Circular Dichroism 
DBU = 1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCC = N,N’-Dicyclohexylcarbodiimide 
DCM = Dichloromethane 
DIEA = N,N-Diisopropylethylamine 
DMF = N,N-Dimethyl Formamide 
DNA = Deoxyribonucleic acid 
ECD = Extracellular Domain 
EtOAc = Ethyl Acetate 
Fmoc = 9-Fluorenylmethyloxylcarbonyl 
FN = Fibronectin 
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Gln = Glutamine 
Glu = Glutamic Acid 
Gly = Glycine 
HCTU = N,N,N′,N′-Tetramethyl-O-(6-chloro-1H-benzotriazol-1-
yl)uronium hexafluorophosphate 
hGH = Human Growth Hormone 
hGHR = Human Growth Hormone Receptor 
HOBT = 1-Hydroxybenzotriazole 
HPLC = High Performance Liquid Chromatography 
Ile = Isoleucine 
JAK2 = Janus Kinase 2 
kDd = kilodalton 
LCMS = Liquid Chromatography/Mass Spectrometry 
Leu = Leucine 
Lys = Lysine 
MALDI-TOF-MS = Matrix Assisted Laser Desorption Ionization – Time 
of Flight- Mass Spectrometry 
MDM2 = Murine Double Minute 
MDR = Multi-Drug Resistance 
MeOH = Methanol 
MM = Multiple Myeloma 
MRD = Minimal Residual Disease 
MSA = Methanesulfonic Acid 
NMM = N-Methylmorpholine 
NMP = N-Methylpyrrolidone 
NMR = Nuclear Magnetic Resonance 
Pd = Palladium 
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PDB = Protein Data Bank 
PEG = Polyethylene Glycol 
Pro = Proline 
RGD = Arg-Gly-Asp 
SAR = Structure-Activity Relationship 
Ser = Serine 
SPPS = Solid Phase Peptide Synthesis 
STAT5 = Signal Transducer and Activator of Transcription 5 
®T3P = Propylphosphonic Anhydride 
TEA = Triethylamine 
TFA = Trifluoroacetic Acid 
THF = Tetrahydrofuran 
TLC = Thin Layer Chromatography 
Trp = Tryptophan 
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